NEW YORK, Sept. 2, 2026 /PRNewswire/ — Bayesian Health today announced that its FDA-cleared sepsis flagging device has been approved for a New Technology Add-on Payment (NTAP) under the Centers for Medicare and Medicaid Services’ FY 2027 Inpatient Prospective Payment System Final Rule. Beginning October 1, 2026, hospitals using the technology can receive additional Medicare reimbursement for eligible inpatient cases.

The approval builds on Bayesian’s Breakthrough Technology Designation and FDA clearance in April 2026, and makes Bayesian the first continuous sepsis monitoring technology with both FDA clearance and a dedicated Medicare reimbursement pathway.

“Early detection should be standard infrastructure in every hospital,” said Suchi Saria, PhD, Founder and CEO of Bayesian Health. “Reimbursement is not what makes clinical AI valuable. It’s signal quality clinicians can trust and the end-to-end infrastructure to operationalize those signals into everyday care. What this approval does is remove friction, so proven technology reaches more clinicians and patients faster.”